Recovery and subsequent recurrence in patients with recurrent major depressive disorder

Journal of Psychiatric Research

Volumn 46, Issue 6, 2012, Pages 708-715

  Dunlop, Boadie W ^a   Holland, Peter ^b   Bao, Weihang ^c   Ninan, Philip T ^c   Keller, Martin B ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Antidepressants; Forecasting; Placebo; Recurrence; Venlafaxine

Indexed keywords

PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; POST HOC ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; THERAPY EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PSYCHIATRIC STATUS RATING SCALES; RECOVERY OF FUNCTION; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84861221732     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.03.002     Document Type: Article

References (26)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders DSM-IV 1994, American Psychiatric Association. 4th ed.
2. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
3. Dunlop B.W., Li T., Kornstein S.G., Friedman E.S., Rothschild A.J., Pederson R., et al. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. Journal of Psychiatric Research 2011, 45:96-103.
4. First M.B., Gibbon M., Spitzer R.L., et al. Structured clinical interview for DSM-IV-TR axis I disorders, clinical trials version (SCID-CT) 2007, Biometrics Research, New York State Psychiatric Institute, New York, NY.
5. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Archives of General Psychiatry 1991, 48:851-855.
6. Furukawa T.A., Akechi T., Azuma H., Okuyama T., Higuchi T. Evidence-based guidelines for interpretation of the Hamilton rating scale for depression. Journal of Clinical Psychopharmacology 2007, 27:531-534.
7. Furukawa T.A., Fujita A., Harai H., Yoshimura R., Kitamura T., Takahashi K. Definitions of recovery and outcomes of major depression: results from a 10-year follow-up. Acta Psychiatrica Scandinavica 2008, 117:35-40.
8. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960, 23:56-62.
9. Hansen R., Gaynes B., Thieda P., Gartlehner G., Deveaugh-Geiss A., Krebs E., et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services 2008, 59:1121-1130.
10. Hochstrasser B., Isaksen P.M., Koponen H., Lauritzen L., Mahnert F.A., Rouillon F., et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. British Journal of Psychiatry 2001, 178:304-310.
11. Judd L.L., Paulus L.L., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. American Journal of Psychiatry 2000, 157:1501-1504.
12. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders 1998, 50:97-108.
13. Keller M.B., Lavori P.W., Lewis C.E., Klerman G.L. Predictors of relapse in major depressive disorder. Journal of the American Medical Association 1983, 250:3299-3304.
14. Keller M.B., Trivedi M.H., Thase M.E., Shelton R.C., Kornstein S.G., Nemeroff C.B., et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. Journal of Clinical Psychiatry 2007, 68:1246-1256.
15. Keller M.B., Trivedi M.H., Thase M.E., Shelton R.C., Kornstein S.G., Nemeroff C.B., et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the acute and continuation phases. Biological Psychiatry 2007, 62:1371-1379.
16. Kocsis J.H., Thase M.E., Trivedi M.H., Shelton R.C., Kornstein S.G., Nemeroff C.B., et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. Journal of Clinical Psychiatry 2007, 68:1014-1023.
17. Lepine J.P., Caillard V., Bisserbe J.C., Troy S., Hotton J.M., Boyer P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. American Journal of Psychiatry 2004, 161:836-842.
18. Rush A.J., Kraemer H.C., Sackeim H.A., Fava M., Trivedi M.H., Frank E., et al. ACNP task force. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 2006, 31:1841-1853.
19. Solomon D.A., Keller M.B., Leon A.C., Mueller T.I., Shea M.T., Warshaw M., et al. Recovery from major depression: a 10-year prospective follow-up across multiple episodes. Archives of General Psychiatry 1997, 54:1001-1006.
20. Solomon D.A., Keller M.B., Leon A.C., Mueller T.I., Lavori P.W., Shea M.T., et al. Multiple recurrences of major depressive disorder. American Journal of Psychiatry 2000, 157:229-233.
21. Spijker J., De G.R., Bijl R.V., Beekman A.T., Ormel J., Nolen W.A. Duration of major depressive episodes in the general population: results from the Netherlands mental health survey and incidence study (NEMESIS). British Journal of Psychiatry 2002, 181:208-213.
22. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 1978, 35:773-782.
23. Thase M.E., Gelenberg A., Kornstein S.G., Kocsis J.H., Trivedi M.H., Ninan P., et al. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. Journal of Psychiatric Research 2011, 45:412-420.
24. Yiend J., Paykel E., Merritt R., Lester K., Doll H., Burns T. Long term outcome of primary care depression. Journal of Affective Disorders 2009, 118:79-86.
25. Zimmerman M., Chelminski I., Posternak M. A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. Journal of Nervous and Mental Diseases 2004, 192:595-601.
26. Zimmerman M., Posternak M.A., Chelminski I. Is the cutoff to define remission on the Hamilton rating scale for depression too high?. Journal of Nervous and Mental Diseases 2005, 193:170-175.